Colin Brenan

Colin J.H. Brenan is a serial life sciences entrepreneur who is the CEO of Kibur Medical Inc., a company closing the translational research gap with a proprietary, in vivo pathology-driven technology that brings the laboratory to the patient, allowing drug developers to make better choices that accelerate their development programs and clinicians to select therapies that improve patient outcomes. Previously he was Founder/CEO & Director of the single-cell instrumentation company 1CellBio Inc.; formerly Founder/CCO & Director of an antibody-drug developer HiFiBiO Ltd; and Managing Director of the early-stage investor MonsantoAtlas Seed Fund Alliance at Atlas Venture (Cambridge, USA).

Before Atlas, Dr. Brenan was Director of Strategic Relationships at CIMIT, the MGB Healthcare innovation center (Boston, MA). Before CIMIT, Dr. Brenan was the Founder/CTO & Director of BioTrove Inc. (Woburn, USA), commercializing the OpenArrayTM, a nanofluidic PCR array acquired by ThermoFisher Inc., and RapidFireTM, an HT MS prep system acquired by Agilent Inc.

Dr. Brenan is a prolific inventor (26 US patents, 27 ex-US patents), has published +50 peer-reviewed articles on diverse topics in biomedical science and technology, and has created products with +US$500M in aggregate global sales. He has over a decade of experience in consulting for the NIH and is an active Senior Member of the IEEE EMBS. Dr. Brenan received his B.Sc. (Honours Physics), M. Eng. (Electrical), and Ph.D. (Biomedical Engineering) from McGill University (Montreal, Canada) and completed post-doctoral training at MIT (Cambridge, USA).

Colin is the 2023-2024 Healthtech Core Team Lead on the 2024 IEEE Entrepreneurship Steering Committee.